Free Trial
NASDAQ:PLRX

Pliant Therapeutics (PLRX) Stock Price, News & Analysis

$10.71
-0.49 (-4.38%)
(As of 06/18/2024 ET)
Today's Range
$10.43
$11.23
50-Day Range
$10.71
$15.61
52-Week Range
$10.43
$22.52
Volume
491,264 shs
Average Volume
533,908 shs
Market Capitalization
$646.09 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$45.38

Pliant Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
323.7% Upside
$45.38 Price Target
Short Interest
Bearish
11.04% of Shares Sold Short
Dividend Strength
N/A
Sustainability
-0.73
Upright™ Environmental Score
News Sentiment
0.62mentions of Pliant Therapeutics in the last 14 days
Based on 6 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($3.44) to ($3.71) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

3.89 out of 5 stars

Medical Sector

185th out of 906 stocks

Pharmaceutical Preparations Industry

77th out of 428 stocks

PLRX stock logo

About Pliant Therapeutics Stock (NASDAQ:PLRX)

Pliant Therapeutics, Inc., a clinical stage biopharmaceutical company, discovers, develops, and commercializes novel therapies for the treatment of fibrosis and related diseases in the United States. The company's lead candidate is bexotegrast, an oral, small-molecule, dual selective inhibitor of avß6 and avß1 integrins, which is in phase 2b trials for idiopathic pulmonary fibrosis and in phase 2a trial for primary sclerosing cholangitis. It also develops PLN-1474, an oral, small-molecule selective inhibitor of avß1 for the treatment of liver fibrosis associated with nonalcoholic steatohepatitis; PLN-101095, a dual inhibitor of integrins avß8 and avß1 for the treatment of solid tumors; and PLN-101325 for treatment of muscular dystrophies. Pliant Therapeutics, Inc. was incorporated in 2015 and is based in South San Francisco, California.

PLRX Stock Price History

PLRX Stock News Headlines

The asset beating inflation by 4x
Central Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Precious Metals Guide, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.
The asset beating inflation by 4x
Central Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire investors are buying right along with them. Even Warren Buffett put over $500 million into gold. And with the help of a tax and penalty-free "Trump Loophole, " these investors are investing retirement into gold and other precious metals without having to put up any of their own cash. In our Free Precious Metals Guide, we reveal all the details on how the rich use this loophole to protect and growth their retirement wealth in any economy…and show you how you can use it too.
Pliant Therapeutics Inc (PLRX)
See More Headlines
Receive PLRX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pliant Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
5/06/2024
Today
6/19/2024
Next Earnings (Estimated)
8/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:PLRX
Fax
N/A
Employees
158
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$45.38
High Stock Price Target
$63.00
Low Stock Price Target
$36.00
Potential Upside/Downside
+323.7%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
9 Analysts

Profitability

Net Income
$-161,340,000.00
Pretax Margin
-68,847.98%

Debt

Sales & Book Value

Annual Sales
$248,000.00
Book Value
$7.91 per share

Miscellaneous

Free Float
56,465,000
Market Cap
$646.09 million
Optionable
Optionable
Beta
1.18
10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report

Key Executives

  • Dr. Bernard Coulie M.B.A. (Age 57)
    M.D., Ph.D., President, CEO & Director
    Comp: $996.97k
  • Dr. Keith Lamont Cummings M.B.A. (Age 47)
    M.D., Chief Financial Officer
    Comp: $684.14k
  • Mr. Mike Ouimette J.D. (Age 51)
    General Counsel & Corporate Secretary
    Comp: $606.03k
  • Mr. Johannes P. Hull (Age 49)
    Chief Business Officer
    Comp: $602.51k
  • Dr. Éric Lefebvre M.D. (Age 60)
    Chief Medical Officer
    Comp: $734.41k
  • Dr. Rik Derynck
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Dean Sheppard M.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Bill DeGrado Ph.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Hal Chapman M.D.
    Scientific Founder & Member of Scientific Advisory Board
  • Mr. Craig D. Muir
    Interim Chief Technology Officer

PLRX Stock Analysis - Frequently Asked Questions

Should I buy or sell Pliant Therapeutics stock right now?

9 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Pliant Therapeutics in the last twelve months. There are currently 9 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" PLRX shares.
View PLRX analyst ratings
or view top-rated stocks.

What is Pliant Therapeutics' stock price target for 2024?

9 Wall Street research analysts have issued twelve-month target prices for Pliant Therapeutics' shares. Their PLRX share price targets range from $36.00 to $63.00. On average, they predict the company's share price to reach $45.38 in the next twelve months. This suggests a possible upside of 323.7% from the stock's current price.
View analysts price targets for PLRX
or view top-rated stocks among Wall Street analysts.

How have PLRX shares performed in 2024?

Pliant Therapeutics' stock was trading at $18.11 at the beginning of 2024. Since then, PLRX stock has decreased by 40.9% and is now trading at $10.71.
View the best growth stocks for 2024 here
.

When is Pliant Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 14th 2024.
View our PLRX earnings forecast
.

How were Pliant Therapeutics' earnings last quarter?

Pliant Therapeutics, Inc. (NASDAQ:PLRX) announced its quarterly earnings data on Monday, May, 6th. The company reported ($0.78) EPS for the quarter, missing analysts' consensus estimates of ($0.76) by $0.02.

What ETFs hold Pliant Therapeutics' stock?

ETFs with the largest weight of Pliant Therapeutics (NASDAQ:PLRX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE).

What other stocks do shareholders of Pliant Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Pliant Therapeutics investors own include Pfizer (PFE), CrowdStrike (CRWD), Trevena (TRVN), AbbVie (ABBV), Abbott Laboratories (ABT), Archer-Daniels-Midland (ADM), Akero Therapeutics (AKRO), Advanced Micro Devices (AMD) and Applied DNA Sciences (APDN).

When did Pliant Therapeutics IPO?

Pliant Therapeutics (PLRX) raised $90 million in an initial public offering (IPO) on Wednesday, June 3rd 2020. The company issued 6,000,000 shares at $14.00-$16.00 per share. Citigroup, Cowen and Piper Sandler acted as the underwriters for the IPO and Needham & Company was co-manager.

Who are Pliant Therapeutics' major shareholders?

Pliant Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Price T Rowe Associates Inc. MD (6.56%), First Light Asset Management LLC (5.86%), Vanguard Group Inc. (5.77%), Redmile Group LLC (5.13%), Capital International Investors (2.28%) and Mass General Brigham Inc (0.48%). Insiders that own company stock include Bernard Coulie, Eric Lefebvre, Hans Hull, Keith Lamont Cummings and Mike Ouimette.
View institutional ownership trends
.

How do I buy shares of Pliant Therapeutics?

Shares of PLRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:PLRX) was last updated on 6/19/2024 by MarketBeat.com Staff

From Our Partners